Jan 09, 2023 09:14 PM

BUSINESS

Pfizer’s Paxlovid to Be Dropped From National Subsidy Scheme as Talks Collapse

By Flynn Murphy and Liu Denghui

Breakthrough Covid treatment Paxlovid from Pfizer will go unsubsidized in China from March 31 after negotiations to add it to the nation's medical insurance scheme for the year broke down Sunday. Photo: VCG

Breakthrough Covid treatment Paxlovid from Pfizer will go unsubsidized in China from March 31 after negotiations to add it to the nation's medical insurance scheme for the year broke down Sunday. Photo: VCG

Pfizer Inc.’s breakthrough Covid drug will be excluded from China’s medical subsidy program this year, health officials said, after pricing talks broke down over the weekend.

The National Healthcare Security Administration (NHSA), which oversees the scheme, said negotiations failed due to the high bulk price that Pfizer quoted for the combination antiviral.

You've accessed an article available only to subscribers

Subscribe today for just $.99.

VIEW OPTIONS

Share this article

Open WeChat and scan the QR code

GALLERY

: Gallery: Pests on the Plateau

NEWSLETTERS

Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription

PODCAST

Caixin-Sinica Business Brief: China’s First Homegrown Jet Sets Sights on Airbus and Boeing

00:00

00:00/00:00

MOST POPULAR

1: Cover Story: China’s Tobacco Monopoly Is Swept Up in Corruption Probes

2: China’s Factory Activity Gets Back to Growth, but Recovery Remains Patchy, Caixin PMI Shows

3: China’s EV Industry Calls on Regulators to Curb the Back-Seat Driving

4: In Depth: China’s Proposed New Curbs on Private Securities Funds Spark Controversy

5: China’s Services Sector Continues to Rebound Faster Than Industrial Sector

SPONSORED

OR